Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $1.2 million.

  • Fulcrum Therapeutics' Other Non-Current Assets changed negligibly% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.2 million for FY2024, which is 40.28% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Other Non-Current Assets of $1.2 million as of FY2024, which was down 40.28% from $2.0 million recorded in FY2023.
  • Fulcrum Therapeutics' 5-year Other Non-Current Assets high stood at $2.1 million for FY2022, and its period low was $1.1 million during FY2020.
  • In the last 3 years, Fulcrum Therapeutics' Other Non-Current Assets had a median value of $2.0 million in 2023 and averaged $1.8 million.
  • Per our database at Business Quant, Fulcrum Therapeutics' Other Non-Current Assets surged by 92.77% in 2022 and then plummeted by 40.28% in 2024.
  • Fulcrum Therapeutics' Other Non-Current Assets (Yearly) stood at $1.1 million in 2020, then remained steady at $1.1 million in 2021, then skyrocketed by 92.77% to $2.1 million in 2022, then declined by 4.47% to $2.0 million in 2023, then slumped by 40.28% to $1.2 million in 2024.